Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec

Katsuya Sakai, Head, Marketing, Rare Immunology Franchise, Rare Disease Business Unit Takeda Pharmaceutical’s acute hereditary angioedema (HAE) drug Takhzyro (lanadelumab) is making steady headway in the Japan market since its launch half a year ago, with its sales advancing as...read more